Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2021-07-19
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Identify avocatin b (C17 lipid) in plasma of individuals that consumed 1 avocado.
* Confirm no avocation b present in the plasma of individuals that avoided avocado intake for 7 days.
* Determine the effect of an overnight fast on avocation b detection.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intralumenal Effects on Cholesterol Absorption/Synthesis
NCT00328211
A Carbohydrate-restricted Diet to Reverse Fatty Liver in Adolescents With Obesity
NCT02787668
Effect of Acetyl-L-carnitine on Chronic Pancreatitis
NCT02538146
Impact of Foods on Bile Acids, Metabolites, and Inflammation
NCT05245357
Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis
NCT00004346
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Based on the results of the questionnaires, BMI calculation, and health evaluation, subjects who meet the inclusion and exclusion criteria will be invited to participate in the study. Eligible subjects will be trained on "how to prepare for study visit". This will include instructions for avoiding avocados for at least 7 days prior to the study Visit, fasting overnight (10-12 hours), avoidance of vigorous physical activity, alcoholic and caffeinated beverage consumption for at least 24 hours preceding a study day, maintain regular sleep pattern. If the subject did not get enough sleep during the night preceding a study day, the investigators will reschedule their study day.
STUDY DAY:
Study Day visit will last about 1.5 hours with a 30 minutes follow-up visit 24 h after the start of the study treatment.
On a Study Day visit, subjects will arrive at the clinic after fasting for at least 10 hours and in a well-hydrated and well-rested state. Subjects will be inquired for compliance to avocado-free food at least 7 days prior to study day and details of food intake in the 24-hour period prior to the visit to ensure consistency and compliance with the protocol requirements. After confirming compliance with the \[ protocol, anthropometric measurements, vital signs (blood pressure, heart rate, and ear temperature) will be taken.
A finger prick for fasting blood glucose will be done to confirm the fasting status. A licensed healthcare professional (LHCP) will draw a baseline blood sample using a butterfly needle (Timepoint t=0). After completing a baseline blood draw, subjects will receive an avocado and crackers to eat onsite. After consuming the avocado and crackers, subjects will be given a take-home snack and be discharged and scheduled to come to CNR the following day for an additional blood sample. The subject will be instructed to fast overnight (10-12 hours), and the blood collection time will be anchored to 24 h after the start of the study treatment (avocado).
Blood collection: Blood will be collected a total of 2 times during the entire study period. The investigators will collect 4 mL of blood each time. Over the course of the whole study, the total amount of blood collected will be 8 mL, which is way less than what is allowed for a one-time blood donation (\~550 mL).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Avocado
Identify avocatin b (C17 lipid) in plasma of individuals that consumed 1 avocado.
Avocado
avocado served with crackers as breakfast
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Avocado
avocado served with crackers as breakfast
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Males/females
* 25-70 years of age
Exclusion Criteria
* Sensitive/allergic to avocados
* Allergies to latex or oral allergy syndrome
* Unstable medical conditions such as on dialysis for renal disease, cardiac, gastrointestinal, or hepatic disease, cancer (non-melanoma skin cancer \>5 years ago acceptable, any cancer site \>10yrs without recurrence).
* Pregnant, lactating, intention of pregnancy
* Lost or gained 15 lbs of body weight in last 2 months
* Following restricted or weight loss dietary patterns
* Elevated alcohol intake (7+ drinks/week females; 14+ drinks/week males)
25 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hass Avocado Board
OTHER
Clinical Nutrition Research Center, Illinois Institute of Technology
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Britt Burton-Freeman, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Illinois Insititute of Technology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Nutrition Research Center
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-2021-108
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.